Cannabis Policy Needs to Balance Psychosis Risk with Medicinal Potential | Research

The takeaway

An editorial in the British Journal of Psychiatry argues that cannabis policy should simultaneously reduce psychosis-related harms from recreational use while improving access to potentially beneficial medicinal cannabis products.

Policymakers, psychiatrists, mental health advocates, cannabis reform advocates

Policy paradox: recreational cannabis widely available while medicinal access restricted

What the researchers found

Cannabis use increases the risk of psychosis, but cannabis-based medicinal products may provide additional therapeutic opportunities. The author notes a policy paradox: decriminalization has led to wider recreational availability in some jurisdictions, while in the UK, regulated medicinal preparations remain difficult to access. A more balanced approach could reduce harms while maximizing potential therapeutic benefits.

Why it matters

This perspective from a leading psychiatric journal frames the cannabis policy challenge clearly: the same plant that poses psychosis risks also contains compounds with therapeutic potential. Policies that address only one side of this equation miss the full picture.

The numbers in context

An estimated 219 million cannabis users globally (referenced in related literature). Cannabis use increases psychosis risk (well-established). UK medicinal cannabis remains difficult to access despite legalization.

How the study worked

Editorial commentary in the British Journal of Psychiatry examining the tension between cannabis-related psychosis risk and medicinal cannabis potential, with policy recommendations.

What this study cannot tell us

Brief editorial commentary (1-2 pages) rather than a comprehensive review. Represents one author's perspective. UK-focused policy discussion may not directly apply to other jurisdictions.

How to read the evidence

Moderate evidence basis for the underlying claims (cannabis-psychosis link and medicinal potential), though the editorial itself is commentary rather than new research.

When this study was published

2025 editorial in the British Journal of Psychiatry.

The bigger picture

The editorial reflects a growing recognition in mainstream psychiatry that cannabis policy must be more nuanced than simply "for" or "against." The challenge is creating regulatory frameworks that minimize harm from high-potency recreational products while facilitating access to standardized medicinal preparations.

Questions still open

What specific regulatory framework would best balance psychosis prevention with medicinal access? Could potency limits on recreational cannabis reduce psychosis risk while maintaining consumer access? Would improved medicinal cannabis access reduce self-medication with unregulated products?

Common questions

Does cannabis cause psychosis?

The editorial affirms that cannabis use increases the risk of psychosis, a finding supported by substantial research. However, it also notes that specific cannabis-based medicinal products may have therapeutic benefits, highlighting the need for nuanced policy rather than blanket prohibition or permissiveness.

What is the policy recommendation?

The author advocates for a balanced approach that reduces harms from recreational use (particularly psychosis risk) while simultaneously making regulated medicinal cannabis preparations more accessible to patients who could benefit from them.

Read the original research

Cannabis and psychosis: minimising harm while maximising therapeutic potential.

The British journal of psychiatry : the journal of mental science, 1-2

View on PubMed ↗Publisher’s paper ↗

Citation

Patel, Rashmi. (2025). Cannabis and psychosis: minimising harm while maximising therapeutic potential.. The British journal of psychiatry : the journal of mental science, 1-2. https://doi.org/10.1192/bjp.2025.10389